Intravenous magnesium supplementation during cisdiammine-dichloroplatinum administration prevents hypomagnesemia

9Citations
Citations of this article
6Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Ten patients with disseminated testicular cancer were studied during 3 cycles of 20 mg/m2/day × 5 d CDDP combined with bleomycin and vinblastine or etoposide. Five of the patients (= group A) received 0.4 mmol KCl/kg/day and 0.3 mmol MgCl2/kg/day; the other five (= group B) received only KC1 intravenously during the CDDP infusions. In group A no decrease of serum and red blood cell Mg concentration was noted. In group B the serum Mg concentration decreased from 0.84 ± 0.04 mmol/1 to 0.57 ± 0.10 (p < 0.001) on day 47, to 0.64 ± 0.08 (p < 0.005) on day 50 and to 0.72 ± 0.02 (p< 0.05) on day 57. The Mg concentration in the red blood cells decreased, but not significantly in group B. Furthermore, the fractional calcium excretion in group B was significantly lower than in group A during the CDDP infusions. © 1990 Kluwer Academic Publishers.

Cite

CITATION STYLE

APA

Netten, P. M., De Mulder, P. H. M., Theeuwes, A. G., Willems, J. L., Kohler, B. E. M., & Wagener, D. J. T. (1990). Intravenous magnesium supplementation during cisdiammine-dichloroplatinum administration prevents hypomagnesemia. Annals of Oncology, 1(5), 369–372. https://doi.org/10.1093/oxfordjournals.annonc.a057776

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free